In line with these reports, we found that Sox9 was upregulated by treatment of glioma cells with recombinant TGF-β1 (Figure 3C), and Sox9 levels decreased when TGF-β signaling was blocked by a selective inhibitor, LY2109761 (Figure 3D). This evidence concerns the gene SOX9 and central nervous system cancer.